Clinical Trial Update: Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 safety study of phIL-12-005/PPC for recurrent ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• phIL-12-005/PPC

Snippet

Sponsor: EGEN, Inc. | Conditions: Ovarian Neoplasms | Phase 1 | Status: TERMINATED